PubMed Daily Triage — 2026-09-20
Run ID: 2026-09-20-attempt1-20260920T090000Z
Window: 2026-09-19T00:00:00Z → 2026-09-20T09:00:00Z (CRDT)
Status: ✅ SUCCESS · Attempt 1 of 3
Articles retained: 35 (HIGH: 2 · STANDARD: 33 · LOW: 0)
Unsolicited finds: 2
Topics scanned: 10 watchlist + sentinel
🔴 HIGH PRIORITY
1. CheckMate 459 Phase III Biomarkers — Nivolumab vs. Sorafenib in Advanced HCC
PMID: 42762856 · Journal: JHEP Reports · Score: 8/10
Flag: 🟠 NOVEL_TREATMENT
Topics: Precision Oncology · Novel Therapeutics
Study design: Phase III RCT exploratory biomarker analysis (n >200/arm)
Key finding: In CheckMate 459, patients with unaltered Wnt/β-catenin pathway showed significantly improved OS with nivolumab vs. sorafenib (HR 0.66, 95% CI 0.47–0.91); PD-L1 CPS≥10 further enriched benefit (HR 0.55, 95% CI 0.33–0.93); high IFN-γ and low pro-collagen 11 were circulating correlates of efficacy.
Why it matters: Phase III RCT biomarker data directly enabling patient selection for first-line nivolumab in advanced HCC. Wnt/β-catenin status and PD-L1 CPS≥10 provide actionable stratification criteria for ongoing trials and clinical decision-making. BMS author COI declared.
DOI: 10.1016/j.jhepr.2026.102038
2. Integrated Urine + Plasma DNA for Molecular Staging of UTUC
PMID: 42763264 · Journal: European Urology Oncology · Score: 7/10
Flag: 🔴 EARLY_CANCER_DETECTION
Topics: Early Cancer Detection (liquid biopsy) · Precision Oncology
Study design: Prospective validation cohort (n=41)
Key finding: Composite liquid biopsy (utDNA TP53 + plasma ctDNA) for upper tract urothelial carcinoma staging achieved specificity 70% vs. 25% and PPV 74% vs. 53% compared to standard clinical risk factors, with equivalent sensitivity (81%); multivariable OR 8.5 (p=0.004) for muscle-invasive disease prediction.
Why it matters: First integrated urinary + plasma DNA approach for UTUC molecular staging, outperforming standard clinical assessment. Small n=41 limits generalizability but prospective design and strong OR provide a compelling proof-of-concept for neoadjuvant chemotherapy selection.
DOI: 10.1016/j.euo.2026.08.008
🟡 STANDARD — Score 7
3. MEITL Epidemiology and Survival: Pooled Patient-Level Analysis (n=299)
PMID: 42762488 · Journal: Hematological Oncology · Score: 7/10
Flag: 🟡 UNDERSERVED_POPULATION
Topics: Hematologic Malignancies · Rare Diseases
Study design: Pooled retrospective patient-level dataset (n=299 global)
Key finding: Median OS 12 months, PFS 5 months in MEITL; advanced Lugano stage, non-ileal distribution, and LDH ≥250 U/L independently associated with inferior OS; exploratory SCT benefit concentrated in chemosensitive patients (landmark analysis).
Why it matters: Largest MEITL dataset to date defines prognostic landscape and identifies potential SCT benefit in this rare, highly lethal intestinal T-cell lymphoma with no established curative therapy. Directly informs risk stratification and treatment sequencing.
DOI: 10.1002/hon.70262
4. Niemann-Pick Disease Type C in India: Molecular Spectrum + smMIP Assay
PMID: 42761304 · Journal: Frontiers in Pediatrics · Score: 7/10
Flag: 🟡 UNDERSERVED_POPULATION
Topics: Rare Diseases
Study design: Multicenter retrospective observational (n=28, 2010–2026)
Key finding: 32 NPC1/NPC2 variants identified (11 novel, 2 exon deletions); >60% of diagnoses concentrated in the final 4 years after the FRIGE-Sanofi DISHA program; smMIP assay enabled simultaneous SNV + CNV detection in a single cost-effective workflow.
Why it matters: First comprehensive molecular characterization of NPC in India. Program-based affordable testing (DISHA) dramatically accelerated diagnosis. smMIP assay is a scalable, lower-cost model directly applicable to other LMI settings for lysosomal storage disorders.
DOI: 10.3389/fped.2026.1950899
5. GLP-1 CNS Effects: Systematic Review of 37 Human Neuroimaging Studies
PMID: 42762879 · Journal: Neuroscience & Biobehavioral Reviews · Score: 7/10
Flag: 🟢 NEAR_TERM_IMPLEMENTABLE
Topics: Cardiovascular-Metabolic (GLP-1)
Study design: Systematic review (PubMed + Embase, n=37 studies, NIH/NIAAA authorship)
Key finding: GLP-1RAs consistently attenuate reward-related brain responsivity across corticosubcortical circuits; CNS effects are modulated by metabolic phenotype, are most pronounced short-term, and attenuate with prolonged treatment exposure.
Why it matters: Most comprehensive synthesis of GLP-1RA CNS mechanisms in humans to date. Provides mechanistic grounding for rapidly expanding GLP-1RA indications beyond obesity/diabetes: addiction, neurodegeneration, psychiatric disorders. Attenuation over time has implications for treatment duration and cycling strategies.
DOI: 10.1016/j.neubiorev.2026.106990
6. CTV Omission in Limited-Stage SCLC: Multicenter Real-World Study (n=946)
PMID: 42763051 · Journal: Radiotherapy and Oncology · Score: 7/10
Flag: ⚪ PROMISING_PRELIMINARY
Topics: Novel Therapeutics
Study design: Multicenter propensity-score-matched observational study (n=946; matched n=265/group)
Key finding: CTV omission: equivalent PFS (11.8 vs 11.6 months) and OS (35.8 vs 30.7 months) vs standard CTV; grade≥3 pneumonitis reduced (3.4% vs 8.3%, p=0.004); among immunotherapy recipients, OS not reached vs 26.9 months with CTV (HR 0.31, p=0.018).
Why it matters: Largest real-world evidence for CTV omission in LS-SCLC. Toxicity reduction is clinically meaningful; immunotherapy interaction with dramatically improved survival is striking and merits prospective confirmation. Practice-changing potential for radiation planning in immunotherapy era.
DOI: 10.1016/j.radonc.2026.111784
🟢 STANDARD — Score 6
7. sCD25/Ferritin Ratio for Lymphoma-Associated HLH Diagnosis (n=126)
PMID: 42762796 · Journal: Leukemia Research · Score: 6/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
Topics: Hematologic Malignancies
AUC=0.74, cutoff >1.02: 73% sensitivity, 73% specificity, 83% NPV for LAHS vs non-LAHS in 3-center US cohort. Practical biomarker from routine labs; best as risk-enrichment tool for occult lymphoma workup in HLH.
DOI: 10.1016/j.leukres.2026.108321
8. Integrated ctDNA + Imaging in Advanced Melanoma: Spatial/Temporal Heterogeneity
PMID: 42760578 · Journal: Journal of Translational Medicine · Score: 6/10 · ⚪ PROMISING_PRELIMINARY
Topics: Early Cancer Detection
Longitudinal ctDNA frequently discordant with radiologic response, capturing tumor heterogeneity undetectable by imaging alone. Supports integrated ctDNA-imaging monitoring as a more complete treatment response picture.
DOI: 10.1186/s12967-026-08899-0
9. Tirzepatide Abdominal Adiposity — SURMOUNT-J Japanese Sub-study (n=225)
PMID: 42762980 · Journal: Endocrine Practice · Score: 6/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
Topics: Cardiovascular-Metabolic
Tirzepatide 10/15 mg: strong VAT reduction (r=0.72–0.84 with weight loss), +78–88% adiponectin, −57–65% leptin, −55–65% CRP vs placebo. Anthropometric surrogates track VAT well in Japanese patients. Lilly COI declared.
DOI: 10.1016/j.eprac.2026.09.006
10. SEG.A 2023: Aortic Vessel Tree Segmentation Challenge Benchmark
PMID: 42762598 · Journal: Medical Image Analysis · Score: 6/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
Topics: AI/ML in Clinical Diagnostics
International multi-team challenge benchmarks transformer/U-Net hybrid methods for aortic CTA segmentation; clinically viable accuracy established; sets deployment-ready performance standards.
DOI: 10.1016/j.media.2026.104324
11. CRISPR Gene Editing in Prostate Cancer: Clinical Applications Review
PMID: 42763006 · Journal: Critical Reviews in Oncology/Hematology · Score: 6/10 · ⚪ PROMISING_PRELIMINARY
Topics: Precision Oncology · Novel Therapeutics
Reviews CRISPR/Cas9 and base-editing approaches targeting AR, PTEN, TP53, BRCA1/2 in prostate cancer; highlights first-in-human trial translation; delivery and off-target challenges remain.
DOI: 10.1016/j.critrevonc.2026.105610
12. T-Cell Exhaustion and Senescence: Regulatory Circuits and Therapeutic Engineering
PMID: 42762964 · Journal: Cancer Letters · Score: 6/10 · ⚪ PROMISING_PRELIMINARY
Topics: Precision Oncology · Novel Therapeutics
Maps TOX/NR4A transcription factor hierarchies, EZH2/TET2 epigenetic remodeling, and metabolic dysfunction driving T-cell exhaustion; synthesizes epigenetic reprogramming + metabolic strategies synergizing with checkpoint blockade.
DOI: 10.1016/j.canlet.2026.218841
13. Inflammaging Couples Bone-Brain Aging: Mechanistic Review
PMID: 42761784 · Journal: Frontiers in Immunology · Score: 6/10 · ⚪ PROMISING_PRELIMINARY
Topics: Aging, Longevity, Population Health
Osteoclast-derived IL-6/TNF-α and DAMPs cross BBB to drive neuroinflammation; bone-derived osteocalcin/lipocalin-2 regulate hippocampal function. Bone-brain axis proposes dual-target therapeutic opportunities in aging.
DOI: 10.3389/fimmu.2026.1874465
14. Brain-Age Estimation Using Ultra-Low-Field MRI: Validation Study
PMID: 42761967 · Journal: Imaging Neuroscience · Score: 6/10 · ⚪ PROMISING_PRELIMINARY
Topics: Aging · AI/ML in Clinical Diagnostics
ULF portable MRI brain-age shows moderate agreement with high-field estimates; demonstrates early feasibility for democratizing brain-age biomarkers in LMI settings; preprocessing pipeline optimization remains a gap.
DOI: 10.1162/IMAG.a.1352
15. Lp(a) + MASLD Synergistically Predict Carotid Atherosclerosis: Large-Scale Study
PMID: 42763236 · Journal: Nutrition, Metabolism and Cardiovascular Diseases · Score: 6/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
Topics: Cardiovascular-Metabolic
Synergistic association of elevated Lp(a) + MASLD with carotid atherosclerosis in cross-sectional and longitudinal analyses; supports dual-biomarker integration into cardiometabolic screening.
DOI: 10.1016/j.numecd.2026.104850
16. Acute Leukemia Immunophenotyping in Conflict-Affected Yemen
PMID: 42762201 · Journal: Libyan Journal of Medicine · Score: 6/10 · 🟡 UNDERSERVED_POPULATION
Topics: Hematologic Malignancies
Integrating immunophenotyping + morphology improved acute leukemia classification at Sana'a National Oncology Center in conflict/LMIC setting; identifies cases misclassified by morphology alone; demonstrates feasibility in extreme resource constraints.
DOI: 10.1080/19932820.2026.2735579
17. Leptin-Melanocortin Pathway Variants in Severe Early-Onset Obesity (Greece)
PMID: 42761221 · Journal: Obesity Pillars · Score: 6/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
Topics: Rare Diseases
Multiple actionable variants identified qualifying patients for setmelanotide (MC4R pathway agonist); supports genetic screening as standard practice in pediatric/adult severe early-onset obesity for precision pharmacotherapy eligibility.
DOI: 10.1016/j.obpill.2026.100330
18. ⭐ UNSOLICITED: Wearable-Measured Fragmented Sedentary Behavior → CVD + Mortality
PMID: 42763296 · Journal: J Central South University (Medical Sciences) · Score: 6/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
Topics: Sentinel (unsolicited find)
Fragmented sedentary behavior (more, shorter bouts) associated with reduced CVD risk and improved life expectancy vs. continuous sedentary time of equal total duration, independent of activity level. Directly actionable behavioral intervention target.
DOI: 10.11817/j.issn.1672-7347.2026.260193
⚪ STANDARD — Score 5
| PMID | Title (abbreviated) | Topics | Flag | Score |
|---|---|---|---|---|
| 42762609 | Oncolytic virotherapy + CAR-T interface: review | T6 | ⚪ | 5 |
| 42761421 | ctDNA MRD in non-metastatic NSCLC: review | T3, T5 | ⚪ | 5 |
| 42762611 | CD4 expression and prognosis in de novo AML | T1 | ⬜ | 5 |
| 42762176 | CLL infiltrative nephropathy: systematic review | T1 | ⬜ | 5 |
| 42762963 | HMGB1 restrains CD8+ T-cell immunity in radiotherapy (preclinical) | T6 | ⚪ | 5 |
| 42762981 | GLP-1 RA body composition (BIA), real-world Spain | T7 | ⬜ | 5 |
| 42762937 | Lenalidomide ferroptosis in MM: c-Maf/USP7/FTH1 (preclinical) | T1, T6 | ⚪ | 5 |
| 42761075 | Medical expense protection for rare disease patients (China policy) | T9 | 🟡 | 5 |
| 42762664 | p53 co-mutations in EGFR-mutant NSCLC: review | T5 | ⬜ | 5 |
| 42763237 | Steatotic liver phenotypes + cardiac autonomic dysfunction (China) | T7 | ⬜ | 5 |
| 42762966 | CD20 nanomedicine + cGAS/STING in DLBCL (preclinical, low conf) | T1, T6 | ⚪ | 5 |
⬛ STANDARD — Score 4
| PMID | Title (abbreviated) | Topics | Flag | Score |
|---|---|---|---|---|
| 42760813 | dd-cfDNA confounders in pediatric heart transplant | T3 | ⬜ | 4 |
| 42761043 | Federated privacy-preserving kidney CT classification (T2 false positive → T4) | T4 | ⬜ | 4 |
| 42762659 | BenSParX: ML Parkinson's detection from Bengali speech | T4 | 🟡 | 4 |
| 42761608 | EPA-PC binding to GCase in Gaucher disease (computational) | T9 | 🟡 | 4 |
| 42763288 | ⭐ UNSOLICITED: Modified SOFA score prehospital — validated thresholds | Sentinel | 🟢 | 4 |
| 42763297 | Humidity × frailty × incident stroke risk: Chinese prospective cohort | T8 | ⬜ | 4 |
Coverage Summary
| Topic | Raw | Reviewed | HIGH | STD | LOW | Notes |
|---|---|---|---|---|---|---|
| T1 Hematologic malignancies | 25 | 15 | 0 | 5 | 10 | |
| T2 CBC/ML hematology | 1 | 1 | 0 | 0 | 1 | False positive (→ T4); zero genuine CBC/ML articles this window |
| T3 Early cancer detection | 7 | 7 | 1 | 3 | 3 | All reviewed (below 15-cap) |
| T4 AI/ML diagnostics | 92 | 15 | 0 | 3 | 12 | Large raw pool; 3 retained |
| T5 Precision oncology | 48 | 15 | 1 | 4 | 10 | |
| T6 Novel therapeutics | 63 | 15 | 1 | 4 | 10 | PMID 42762856 shared with T5 |
| T7 Cardiometabolic | 48 | 15 | 0 | 5 | 10 | |
| T8 Aging/longevity | 19 | 15 | 0 | 3 | 12 | |
| T9 Rare diseases | 10 | 10 | 0 | 4 | 6 | All reviewed (below 15-cap) |
| Sentinel | 698 | 10 | 0 | 2 | 8 | 2 unsolicited finds retained |
Scoring Reference
| Axis | Max | Description |
|---|---|---|
| novelty | 3 | Novel finding vs. incremental |
| relevance | 3 | Match to watchlist topic |
| design_quality | 2 | Study design strength |
| population_or_unmet_need | 2 | Population breadth / unmet need |
| Total | 10 |
Pipeline priority: HIGH if score ≥8 OR flag=EARLY_CANCER_DETECTION/NOVEL_TREATMENT; STANDARD if 4–7; LOW if ≤3.
Non-human/preclinical cap: triage_score ≤5 (applies to PMID 42762937, 42762963, 42762966).
Generated by Friday (OpenClaw main agent) · 2026-09-20T09:05:00Z
Attempt 1 of 3 · Schema v1.3 · Window: CRDT 2026-09-19T00:00Z → 2026-09-20T09:00Z